Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism Complete
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolic events, pulmonary embolism List with criteria/condition Complete
Xalkori Crizotinib ROS1-positive advanced non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Xalkori Crizotinib Advanced Non-Small Cell Lung Cancer Do not reimburse Complete
Xalkori Crizotinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Xalkori Crizotinib First Line ALK Positive Advanced NSCLC Reimburse with clinical criteria and/or conditions Complete
Winlevi clascoterone Acne vulgaris Withdrawn
Welireg belzutifan von Hippel-Lindau disease-associated tumours Reimburse with clinical criteria and/or conditions Complete
Wegovy semaglutide Weight management Do not reimburse Complete